Labiotech.eu

News and Trends 15 Oct 2015

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

Minoryx Therapeutics is a Barcelona based Rare-disease specialist who has a panel of orphan-drug experts for their discovery program. Now backed in a €19.4M Series A round from leading VC firms Ysios (No 15 in our top EU VCs) and Roche Venture Fund, Minoryx will have the well-needed cash to push for further R&D of their […]

October 15, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

New Oncology from Cologne (Germany) is a biotech which today published a paper in Nature on tumor-profile recognition of cancer of the sympathetic nervous system (Neuroblastoma) in conjunction with the latest research at the University of Cologne. The research team has found a new way to diagnose infants with the deadly high-risk version of Neuroblastoma, which […]

October 14, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011. This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Oct 2015

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand […]

October 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

No, Novartis and Roche won’t merge (yet)!

Novartis already owns 33% of Roche, but even if both companies are headquartered in the same city of Basel (Switzerland), they still have no plans to merge. Joerg Reinhardt, The Chairman of Novartis – the second biggest Pharma company worldwide by market cap (€212Bn – J&J: €231Bn), was asked about it on the Swiss TV Bilanz […]

October 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Oct 2015

Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

The Hemophilia Aid Program has just touched down the first batch of treatments in its target developing countries, as part of a 10-year commitment from US Biogen (Massachusetts) and Swedish Orphan Biovitrum AB (SOBI) from Stockholm via the World Federation of Hemophilia (WFH)’s AID project. The relief effort pledges to ship over 1 billion units […]

October 13, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 13 Oct 2015

Why can’t Novartis Commit to the Israeli Biotech Scene?

Novartis, the Swiss Acquisition-Giant from Basel, has once again taken bought a small chunk of shares from the Israel biotech scene for only $15M (2.5%), instead of making a final solid purchase. The Jerusalem biotech Gamida Cell, which has a stem-cell therapies for hematological diseases (leukemia and various types of anemia), was underwhelmed a second […]

October 13, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 13 Oct 2015

The Top 15 European Biotech VCs

Biotech wouldn’t exist without Venture Capitalists. These investors bring the cash necessary to run clinical trials or conduct the scaling-up of processes, along with many years of experience. Though admittedly Europe definitely hasn’t got as much money floating around as the US, there are many major Biotech VCs in Europe … Here are 15 of […]

October 13, 2015 - 9 minutesmins - By Philip Hemme

News and Trends 12 Oct 2015

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Monellin chain B is an artificial sweetener initially mistaken for a carbohydrate. It has since been established to actually be a natural protein based sweetner which is fairly unstable. iSweetch from the University of Naples has used E. Coli to engineer a more stable version of the protein to revolutionize the artificial sweetner industry. Monellin […]

October 12, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Oct 2015

What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research

Monday: Manfred Horst on MSD, Biosimilars, KEYTRUDA and Merck & Co.’s rich history Tuesday: An Insider’s experience at the iGEM Giant Boston Jamboree 2015 Wednesday: Sorry CRISPR, you’ll have to wait another year to win a Nobel Prize! Thursday: The Future Biotech Lab Bench: My experience of the cutting edge-tech at LABVOLUTION Friday: Alzheimer’s Disease: Phase III breakthrough Tau-therapy earns […]

October 10, 2015 - 1 minutemin - By Philip Hemme

News and Trends 9 Oct 2015

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

As we reported last Monday, the AbbVie–Galapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Spanish connection: VC leads Biotech series A Fund to cure Rare Neurodegenerative Disease

High-Risk Infant Cancer: Nature publishes on a New and Reliable Biomarker from Cologne

Innate Pharma receives $5M from its Monster-deal with BMS

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

No, Novartis and Roche won’t merge (yet)!

Global Hemophilia AID project achieves first milestone with donations from Swedish Biotech

Why can’t Novartis Commit to the Israeli Biotech Scene?

The Top 15 European Biotech VCs

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!